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Background: Scientific evidence supports decision-making on the use of implantable medical devices (IMDs) in
clinical practice, but IMDs are thought to be far less investigated than drugs. In the USA, studies have shown that
approval process of high-risk medical devices was often based on insufficiently robust studies, suggesting that
evidence prior to marketing may not be adequate. This study aimed to ascertain level of evidence available for
IMDs access to reimbursement in France.
Methods: The objective was to examine the scientific evidence used for IMDs assessment by the French National
Authority for Health. We collected all public documents summarising supportive clinical data and opinions
concerning IMDs issued in 2008. An opinion qualifies the expected benefit (EB) of the IMD assessed as sufficient or
insufficient, and if sufficient, the level of improvement of the expected benefit (IEB) on a scale from major (level I)
to no improvement (level V). For each opinion, the study with the highest level of evidence of efficacy data, and its
design were collected, or, where no studies were available, any other data sources used to establish the opinion.
Results: One hundred and two opinions were analysed, with 72 reporting at least one study used for assessment
(70.6%). When considering the study with the highest level of evidence: 34 were clinical non-comparative studies
(47.2%); 29 were clinical comparative studies of which 25 randomised controlled trials (40.3%); 5 were meta-analyses
of randomised controlled trials (6.9%); and 4 were systematic literature reviews (5.6%). The opinions were
significantly different according to the study design (p < 0.001). The most frequent design for insufficient EB, IEB
level V and IEB level IV was a non-comparative study (10/19, 52.6%; 15/24, 62.5%; and 8/15, 53.3%; respectively). For
the 30 opinions with no supporting clinical study, 16 (53.3%) were based on an expert-based process, 9 (30.0%)
were based on the conclusions of a previous opinion (all concluding IEB level V), and 5 (16.7%) reported no data
(concluding insufficient EB for 4 and IEB level V for 1).
Conclusions: This study confirmed that level of evidence of clinical evaluation of IMDs is low and needs to be
improved.
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By the late 1990s, the US Food and Drug Administration
(FDA) had given marketing approval to around 500,000
medical devices, produced by approximately 23,000 dif-
ferent manufacturers, and it has been estimated that 4%
of the US population has at least one implanted medical
device [1,2]. The US medical device market was esti-
mated in 2011 at US$105.8 billion. In Europe, there
are almost 22,500 medical technology firms, which
generate annual sales of €95 billion [3]. In 2006, the
medical device market in France comprised €19 billion
in sales, representing 12% of medical and health care
consumption [4].
Most new medical technologies are intended to im-
prove quality of care but they also increase health spend-
ing [5]. For this reason Health Technology Assessment
(HTA), which is defined as the systematic evaluation of
the properties, effects, and/or impacts of healthcare
technology [6], has been developed to inform healthcare
providers, payers and patients about technology-related
clinical and cost effectiveness. In France, the government
set up the French National Authority for Health (Haute
Autorité de Santé, HAS) in August 2004, whose activities
are designed to improve the quality of patient care and
guarantee equity within the healthcare system. These ac-
tivities include the assessment of medical devices based
on scientific expertise, carried out by a dedicated com-
mittee (Commission Nationale d’Evaluation des Disposi-
tifs Médicaux et Technologies de Santé, CNEDIMTS) [7].
The aim of these assessments is to provide “opinions” to
health authorities that contain the information needed
to support decisions regarding the reimbursement. All
assessed medical devices qualified with “sufficient
expected clinical benefit” are included on the list of pro-
ducts and services qualifying for reimbursement [8].
In this context, a manufacturer who seeks reimburse-
ment by the French Health Insurance system for the cost
of a medical device has two options. If the medical de-
vice responds to a generic definition already included on
the list qualifying for reimbursement, it can be registered
directly. In case there is no generic definition for the
medical device, the manufacturer has to apply for spe-
cific CNEDIMTS’ assessment (brand name registration),
and to submit a dossier containing clinical data. These
data should demonstrate the value of the medical device,
i.e. what is the expected clinical benefit and whether it is
sufficient to justify its inclusion on the list qualifying for
reimbursement, and should propose what improvement
in terms of clinical benefit may be expected in compari-
son with the existing standard of care. The CNEDIMTS’
members base their scientific assessment on the synthe-
sis of information performed by internal assessors, from
clinical data provided by the manufacturers or retrieved
from an in-house scientific literature search. They focusspecifically on the following features of studies: meth-
odological quality; selection of a relevant population;
main outcome measure; and adverse events and compli-
cations related to the procedure. For every assessment, a
public document summarising supportive clinical data
and providing the opinion is available on the French Na-
tional Authority for Health’s website [7].
Previous studies have shown that the approval process
for high-risk medical devices in the USA is often based
on insufficiently robust studies, suggesting that evidence
prior to marketing may not be adequate [9,10]. This
study aimed to ascertain what level of evidence was
available for IMDs access to reimbursement in France.
Therefore, we have described the scientific evidence, in
terms of the methodology and characteristics of the clin-
ical studies used by CNEDIMTS for implantable medical




An opinion is the result of CNEDIMTS assessment of
safety and efficacy of a device in a specified indication,
expressed by the qualification of its “expected benefit”
(EB) as insufficient or sufficient; in the latter case its
“improvement of expected benefit” (IEB) level is docu-
mented. EB is a multifactor criterion based on expertise
of clinical benefit, efficacy/safety ratio, and public health
benefit. IEB is given in comparison to the established
standard of care: level I means there is a major improve-
ment in expected benefit with the IMD; level II is a
significant improvement; level III is a moderate im-
provement; level IV is a minor improvement; and level
V is no improvement. An IMD could be used in differ-
ent indications, resulting in one opinion for each indica-
tion. Therefore there could be more opinions than
devices; the statistical unit for this study was one
opinion, given for one IMD used for one precise clinical
indication.
Opinions can be issued for a new application (first or
subsequent), a modification, or a renewal. A “new appli-
cation” was considered as “first”, only for the first appli-
cation, and as “subsequent” when re-application was due
to a previous insufficient EB opinion. After the IMD is
included on the list, each modification (e.g. restriction of
use or indication) must be assessed by CNEDIMTS.
Every 5 years (maximum) after inclusion on the list, a re-
newal application must be submitted, leading to assess
the observed benefit and the improvement of observed
benefit. For convenience, EB will refer to both expected
(new application) and observed (renewal application)
benefit.
Public documents presenting opinions summarise in-
formation on clinical data: the number of studies
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selected by CNEDIMTS for the assessment process, and
the abstract outlining the main characteristics of selected
studies (design, number of patients, results). Supporting
clinical data are specific or non-specific to the device
assessed. Non-specific data relating to the device come
from studies performed on an equivalent medical device
(same technological characteristics and same intended
use) i.e. previous model or device manufactured by a
competitor.
Search and opinion selection
The present study included all opinions concerning
IMDs issued by the CNEDIMTS in 2008 and publicly
available on the website of the French National Author-
ity for Health (http://www.has-sante.fr).
Data collection
For each opinion, two reviewers (LH and ED) independ-
ently examined and collected the data using predefined
case report forms. Discrepancies between the two
reviewers were resolved by consensus.
Study selection within opinions Only studies reporting
efficacy were examined. For modification or renewal
applications, only the new clinical data, i.e. that became
available since the previous opinion, were considered.
The reviewers extracted the number of studies: i) pro-
vided by the manufacturer (when explicitly provided);
and ii) selected by CNEDIMTS (including those from
manufacturer and those from the in-house literature
search) as mentioned in its opinion.
Among the studies selected by CNEDIMTS, the one
presenting the highest level of evidence was chosen for
methodological description, whether it was specific or
non-specific to the device. The levels of evidence of the
studies were defined as follows (from the highest to the
lowest [11]): 1) meta-analysis of randomised controlled
trials (RCTs); 2) RCTs; 3) non-randomised comparative
studies; 4) non-comparative studies i.e. meta-analysis of
non-comparative studies, prospective observational
registries, prospective case-series, and retrospective
case-series. Systematic literature reviews were consid-
ered if no specific study was available. When two studies
had the same level of evidence, the one with the highest
number of patients was analysed.
Data items The following general information was
extracted: the date of the opinion; the year of the CE
marking (Conformité Européenne); the type of applica-
tion i.e. new application (first or subsequent), modifica-
tion, or renewal; the date of previous opinion if relevant;
and the opinion result i.e. EB qualification (sufficient or
insufficient) and IEB level.The following main methodological characteristics of
the highest level of evidence studies, as available in pub-
lic documents, were collected:
– number of centres (single centre, national
multicentre, and international multicentre);
– study design (as described above);
– total number of patients included in statistical
analysis;
– output (statistical significance of the main result).
When no studies had been retained as scientifically
sound by the CNEDIMTS, we collected the other
sources of data (if any) used to provide the opinion.
Data analysis
The categorical variables were described as frequencies
and percentages, and the continuous variables as average
or median and range (minimum and maximum). For
analysis, we considered a variable “EB + IEB” defined
with 6 categories: insufficient EB, IEB level V, IEB level
IV, IEB level III, IEB level II, and IEB level I. Types of
application and collected studies characteristics were
cross-tabulated with the results of the opinions (EB +
IEB), and types of application were cross-tabulated with
study design. Fisher exact tests were used. All data ana-
lyses were performed using SAS version 9.2 (SAS Insti-
tute Inc, Cary, NC).
Results
Description of opinions
A total of 171 public documents were issued by the
CNEDIMTS for medical devices in 2008; 83 concerning
93 IMDs were included in the analysis (Figure 1), repre-
senting 102 opinions.
Seventy-nine opinions (77.5%) resulted in sufficient EB
(Table 1). One IEB level I was observed (deep brain
stimulation medical device).
Sixty-six percent of the opinions resulted from new
applications (67/102). The opinions were issued a me-
dian of 5.0 years after the CE marking for first new
applications (range: 0.0 to 12.0). Concerning subsequent
new applications, the new opinion was given a median
of 4.4 years after the previous application (range: 2.9 to
6.1). Opinions concerning renewals were given after a
median of 3.0 years following the previous one (range:
1.5 to 6.0).
EB + IEB differed according to the type of application
(p = 0.002). Of the 23 opinions with insufficient EB, 21
were new applications (91.3%).
Description of clinical data
For 70/102 opinions (68.6%), at least one clinical study
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Figure 1 Flow diagram of opinion selection.
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number of studies provided was available for 54 opi-
nions; median: 2, range: 1 to 15). The CNEDIMTS ana-
lysed clinical studies in 72/102 opinions (70.6%), with an
average of 3.2 selected and analysed studies (median: 2,
range: 1 to 15).
Among these, the study with the highest level of evi-
dence concerned the relevant medical device in 45/72
studies (62.5%), a previous model 15/72 (20.8%) and a
similar model in 12/72 (16.7%).
The main methodological characteristics of these stud-
ies are shown in Table 2.
The study design was significantly different according
to EB + IEB (p < 0.001). The most frequent design was
non-comparative studies for insufficient EB (10/19;
52.6%), IEB level V (15/24; 62.5%) and IEB level IV (8/
15; 53.3%); randomised controlled trials for IEB level IIITable 1 Distribution of the Expected Benefit and Improvemen
application
Total N (%) New N (%)
Sufficient EB* 79 (77.5) 46 (68.7)
IEB† level I 1 (1.0) 0 (0.0)
IEB level II 8 (7.8) 2 (3.0)
IEB level III 5 (4.9) 3 (4.5)
IEB level IV 15 (14.7) 11 (16.4)
IEB level V 50 (49.0) 30 (44.8)
Insufficient EB 23 (22.5) 21 (31.3)
Total 102 67
* EB: expected benefit.
† IEB: improvement of expected benefit.(3/5; 60.0%) and IEB level I (1/1); and meta-analysis for
IEB level II (5/8; 62.5%).
The study design was significantly different according
to the type of application (p = 0.006), e.g., for the 45 new
applications, there were 24 non-comparative studies
(53.3%) compared with 5 for the 18 renewals (27.8%).
For the 30 opinions with no supporting clinical study,
16 (53.3%) were based on CNEDIMTS expert-based ana-
lysis (involving multidisciplinary working group using
medical device group information: literature analysis and/
or previous opinions): 12 concerned implantable cardiac
defibrillators; three prosthetic meshes for hernia repair;
and one a triple-chamber pacemaker. All concluded with
IEB level V. Nine opinions (30.0%) were based on the con-
clusions of a previous opinion (all concluded with IEB
level V). The last 5 opinions reported no data and con-
cluded with insufficient EB for 4, and IEB level V for 1.t of Expected Benefit level according to the type of
Modification N (%) Renewal N (%)
13 (92.9) 20 (95.2)
1 (7.1) 0 (0.0)
0 (0.0) 6 (28.6)
1 (7.1) 1 (4.8)
1 (7.1) 3 (14.3)
10 (71.4) 10 (47.6)
1 (7.1) 1 (4.8)
14 21
Table 2 Description of methodological characteristics of the highest level of evidence studies considered for
assessment of implantable medical devices (one study analysed per opinion)
Overall
N (%)
Sufficient Expected Benefit (EB*) Insufficient
EB
IEB* I IEB II IEB III IEB IV IEB V
Number of centres†
Single centre 12 (19.7) 0 0 1 2 4 5
National multicentre 16 (26.2) 0 1 0 4 8 3
International multicentre 12 (19.7) 1 0 2 3 1 5
Not known 21 (34.4) 0 2 1 5 9 4
Design
Meta-analysis of RCTs{ 5 (6.9) 0 5 0 0 0 0
RCTs 25 (34.7) 1 3 3 7 7 4
Comparative non-randomised study 4 (5.6) 0 0 0 0 1 3
Non-comparative study 34 (47.2) 0 0 1 8 15 10
Retrospective case series 5 (14.7) 0 0 0 0 2 3
Prospective cohort 21 (61.8) 0 0 1 5 9 6
Observational registry 6 (17.6) 0 0 0 2 3 1
Meta-analysis of non comparative study 2 (5.9) 0 0 0 1 1 0
Systematic literature review 4 (5.6) 0 0 1 0 1 2
Number of patients}
(median (range)) 127.5 (8-18 023) 40 (.) 530 (22-18 023) 568.5 (8-1 065) 67 (15-859) 198 (29-8 318) 62 (19-280)
Output||
Significant result 21 (70.0) 1 8 2 3 4 3
Insignificant result 9 (30.0) 0 0 1 1 4 3
Total 72 (100.0) 1 8 5 15 24 19
* EB: expected benefit; IEB: improvement in expected benefit.
† Non-applicable for 11 studies (meta-analysis and systematic literature reviews).
{ RCTs: randomised controlled trials.
} Non-applicable for systematic literature reviews.
|| For comparative studies and meta-analyses of RCTs only; for 4 the information is missing.
Huot et al. BMC Public Health 2012, 12:585 Page 5 of 7
http://www.biomedcentral.com/1471-2458/12/585Discussion
In 2008, among the clinical studies with the highest
level of evidence assessed by CNEDIMTS, less than
half were RCTs or meta-analysis of RCTs. The EB for
the CNEDIMTS’ opinions on IMDs correlated to the
clinical studies’ level of evidence: low levels of evi-
dence were observed in insufficient EB or low levels
of IEB. When no clinical data was available for assess-
ment, the opinion was more likely to conclude on in-
sufficient EB.
To our knowledge, this study is the first to provide a
description of the methodological characteristics of stud-
ies used during medical device assessment by the French
National Authority for Health, and one of the first
assessments of the decisions issued by a national compe-
tent authority. Its main limitation is the use of publicly
available opinions as a data source: some data may have
been omitted from public documents, as the opinions do
not reveal the complexity of the committee’s decision-
making process.The level of evidence of the clinical studies carried out
is expected to impact coverage and reimbursement
determinations, which indirectly impacts the diffusion of
implantable medical devices in healthcare practices. This
issue is complicated for manufacturers, who argue that
increasing the level of evidence required will create a fi-
nancial and time barrier to putting new products on the
market and restrict patients’ access to new medical tech-
nologies [12,13]. This is even more difficult for smaller
firms, which represent most of medical technology
firms, which may not have the capital to conduct trials
and are not equipped to meet regulatory and methodo-
logical requirements [14].
In Europe, studies assessing the clinical efficacy of
implantable medical devices were not systematically
required for CE marking until the 2007 European Dir-
ective [15]. The regulatory approval for CE marking fo-
cuses on safety, device quality and performance. Very
often only scarce information is available when a new
medical device first comes onto the market. Indeed,
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clinical study for medical devices evaluation [16]. RCTs,
commonly used in drug development and considered to
be the study design which provides the highest level of
evidence for assessing the efficacy of health products,
are particularly prone to methodological challenges
when considering IMDs [17]. Blinding is not always feas-
ible (or unethical, for instance sham surgery). Interaction
between device and operator might induce heterogeneity
in clinical efficacy and safety, such as learning curve ef-
fect, teams’ expertise and habits (need for procedure
standardisation), or continuous technological evolution.
Inclusions in such studies might be difficult, since target
populations are often small.
In the USA, the safety and effectiveness of high-risk
medical devices, such as implantable medical devices,
are assessed by the FDA during the Premarket Approval
(PMA) process which relies on clinical data. Two studies
have shown that PMA for cardiovascular devices be-
tween 2000 and 2007 was often based on studies which
were insufficiently robust and possibly prone to bias, as
only 27% of studies used to support PMA were rando-
mised [9,10]. Furthermore, 65% of PMAs were based on
a single study, suggesting that there may not be adequate
evidence prior to marketing [9]. Even if most Class III
devices should require PMA, it has been discussed that
a large percentage avoid this process and go through
510(k) submission, which is known to be less rigorous
with no systematic need for supportive clinical evidence
[18]. In 2003-2007 fiscal years, 228 Class III devices
had been cleared by FDA through 510(k) process, while
217 had been submitted through original PMA [19].
We showed that a new opinion was given up to
12 years after CE marking. During this time, a new de-
vice may be distributed and widely used by physicians in
their standard practice of care, especially in the case of
innovative devices [20]. Once the medical device has
been distributed, it becomes difficult to assess its clinical
benefit and cost in relation to existing strategies [21].
The main constraint in performing RCTs after device
distribution is that randomisation may not be accepted,
not only by physicians, but also by patients who are well
informed about new technologies and are keen to access
them. Therefore, to determine efficacy and safety, alter-
native approaches to conventional trial designs might be
considered, e.g. use of historical controls and acceptance
of p values greater than 0.05 [22]. It has also been sug-
gested that well-designed comparative observational
studies may provide information for clinical and effect-
iveness assessments [23-25]. Such studies may be per-
formed within a post-marketing surveillance program. In
first place, post-marketing surveillance has been set up
to explore safety concerns such as rare adverse events,
through vigilance reporting. However, specific post-marketing clinical studies have to be developed as they
can offer the opportunity to collect outcomes data [26],
not only for safety but for efficacy purpose. It has been
suggested for high-risk medical devices that a post-
marketing surveillance program should be in place at
the time of market authorisation as a continuum of clin-
ical studies from pre-market to routine use, within a
new regulatory approach [27]. A new model based on
temporary authorisations and post-marketing studies
could be developed. Currently, post market registries are
being increasingly set up to provide real life data about
use, safety and efficacy of IMDs.
HTA for medical devices can guide collective choices
in terms of access to technology, with a view to ensuring
their effectiveness and cost-effectiveness. The lack of sci-
entific data raises ethical issues as offering a new, un-
approved technique outside of a clinical research
context may put the patient at risk. The timely diffusion
of such techniques is vital as there are risks associated
with the premature introduction of a device without suf-
ficient clinical evaluation, just as an excessive waiting
period may be detrimental to patients. There is a serious
question as to when the assessment should be carried
out: if it is done early in the development process, both
the device and procedure may undergo changes and the
learning curve effect has to be incorporated, and the
findings of the assessment may rapidly become obsolete
[28]. Procedures to ensure the “safe” diffusion of innova-
tions has been implemented in European countries as
programmes for funding innovation under the frame-
work of clinical research. A programme to support in-
novative and costly technologies was created in the early
2000s by the French Ministry of Health, with the aim of
supervising their diffusion whilst simultaneously asses-
sing their clinical and cost effectiveness. In the United
Kingdom, a procedure for temporary reimbursement has
been set up for innovative devices when used only in re-
search for the purposes of generating clinical data and
good practice guidelines [29].
Conclusions
This study confirmed that level of evidence of clinical
evaluation of IMDs is low and needs to be improved,
since less than half of clinical studies with the highest
level of evidence assessed by CNEDIMTS in 2008 were
RCTs or meta-analysis of RCTs. Future work should de-
sign new recommendations in this field by investigating
the determinants and the solutions needed to improve
quality of clinical evaluation of medical devices, in con-
nection with small and medium firms, clinicians and
authorities.
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